Geode Capital Management LLC Purchases 58,823 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Geode Capital Management LLC increased its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 10.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 599,119 shares of the company's stock after acquiring an additional 58,823 shares during the period. Geode Capital Management LLC owned approximately 1.39% of Soleno Therapeutics worth $26,937,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of SLNO. Barclays PLC boosted its position in shares of Soleno Therapeutics by 149.3% during the 3rd quarter. Barclays PLC now owns 52,545 shares of the company's stock valued at $2,652,000 after acquiring an additional 31,467 shares during the last quarter. Emerald Advisers LLC lifted its position in Soleno Therapeutics by 85.4% during the fourth quarter. Emerald Advisers LLC now owns 580,919 shares of the company's stock valued at $26,112,000 after purchasing an additional 267,585 shares during the last quarter. State Street Corp grew its stake in Soleno Therapeutics by 14.2% in the 3rd quarter. State Street Corp now owns 1,142,169 shares of the company's stock worth $57,668,000 after buying an additional 142,033 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Soleno Therapeutics by 13.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 217,550 shares of the company's stock worth $9,779,000 after buying an additional 24,953 shares during the last quarter. Finally, Sei Investments Co. raised its position in shares of Soleno Therapeutics by 47.0% during the 4th quarter. Sei Investments Co. now owns 16,444 shares of the company's stock valued at $739,000 after buying an additional 5,258 shares in the last quarter. Institutional investors own 97.42% of the company's stock.

Insider Activity

In other Soleno Therapeutics news, insider Patricia C. Hirano sold 3,782 shares of the company's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $70.11, for a total transaction of $265,156.02. Following the completion of the sale, the insider now directly owns 27,036 shares of the company's stock, valued at approximately $1,895,493.96. This represents a 12.27 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Michael F. Huang sold 14,583 shares of Soleno Therapeutics stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $69.51, for a total transaction of $1,013,664.33. Following the transaction, the vice president now owns 36,817 shares in the company, valued at $2,559,149.67. This represents a 28.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 942,672 shares of company stock valued at $64,058,781 over the last three months. Insiders own 12.30% of the company's stock.

Wall Street Analyst Weigh In

SLNO has been the topic of a number of research analyst reports. UBS Group set a $105.00 target price on Soleno Therapeutics in a research note on Thursday, March 27th. Lifesci Capital upgraded shares of Soleno Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 4th. HC Wainwright restated a "buy" rating and set a $100.00 target price on shares of Soleno Therapeutics in a report on Tuesday, April 15th. Stifel Nicolaus raised their price target on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the stock a "buy" rating in a report on Friday, March 28th. Finally, Laidlaw boosted their target price on Soleno Therapeutics from $75.00 to $105.00 and gave the company a "buy" rating in a research note on Thursday, March 27th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $99.63.

Soleno Therapeutics Trading Up 3.6 %

SLNO stock traded up $2.56 during midday trading on Wednesday, hitting $73.96. The company's stock had a trading volume of 256,762 shares, compared to its average volume of 725,646. The company has a market cap of $3.39 billion, a PE ratio of -22.28 and a beta of -2.29. The firm's 50-day moving average is $55.94 and its 200-day moving average is $52.38. Soleno Therapeutics, Inc. has a 12 month low of $36.93 and a 12 month high of $74.47.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.41). Analysts expect that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.